Compare Regeneron Pharmaceuticals Inc (REGN) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Regeneron Pharmaceuticals Inc vs SkyWest Inc — how do they compare? Regeneron Pharmaceuticals Inc trades at $737.72 (market cap $76.40B), while SkyWest Inc trades at $96.42 (market cap $3.76B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 20.3× SkyWest Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.51% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Regeneron Pharmaceuticals Inc for 107 Days and SkyWest Inc for 8 Days on average.
| REGN | SKYW | |
|---|---|---|
Market Cap | $76.40B | $3.76B |
Volume | 626,381 | 296,298 |
Sector | Health | Industrials |
52-Week High | $852.03 | $115.94 |
52-Week Low | $557.73 | $78.40 |
Typical Hold Time | 107 Days | 8 Days |
Enterprise Value | $71.12B | $5.54B |
Dividend Yield | 0.51% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
SkyWest (SKYW) trades at $96.64, down 1.1% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported mixed earnings, beating in Q1 2026 but missing in Q4 2025 and Q2 2026, with revenue growth from $4.1B in 2025 to $4.2B in 2026. Analyst consensus is bullish with a $112 price target, supported by fleet upgrades and flying agreements, though net income margin dipped to 9.78% in 2026.
The outlook is cautiously optimistic given strong analyst buy ratings and undervalued metrics like a P/E of 9.6, but risks include cost pressures, insider selling, and technical bearishness. Upside hinges on execution of growth initiatives amid competitive and operational headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
